Publications by authors named "F L Mikell"
Article Synopsis
- This study evaluated the effects of sotagliflozin, a medication, on adults with type 1 diabetes over 12 weeks in a double-blind trial comparing different doses to a placebo.
- The results showed that sotagliflozin helped reduce glycated hemoglobin (HbA1c), particularly at the 200 mg and 400 mg doses, and led to a reduction in weight and increased glucose excretion.
- Overall, the medication improved glycemic control without significantly increasing the risk of severe low blood sugar or diabetic ketoacidosis, indicating it could be a beneficial addition to insulin therapy for type 1 diabetes patients.
Background: Stress cardiomyopathy (SCM) is a newly described reversible cardiomyopathy of largely unclear etiology. We studied SCM in a large cohort to gain further insights.
Methods: We retrospectively identified 114 cases of SCM from among 12,150 consecutive North American patients diagnosed as Troponin-positive acute coronary syndrome, from January 2000 through December 2007, at two 24-h coronary angioplasty-capable centers.
Background: In Europe, interhospital transfer of ST-elevation myocardial infarction (STEMI) patients for primary percutaneous coronary intervention (PCI) from non-PCI-capable (STEMI-referral) to PCI-capable (STEMI-accepting) facilities has been shown to be a superior reperfusion strategy compared with on-site fibrinolysis. The feasibility of such programs in the United States remains poorly defined.
Methods And Results: We describe an observational cohort of 230 consecutive presumed STEMI patients who underwent interhospital transfer between January 2005 and March 2007 among 6 STEMI-referral and 2 STEMI-accepting hospitals in rural central Illinois.
Objective: To assess costs and outcomes of coronary stenting and balloon angioplasty with and without adjunctive treatment with abciximab for 3758 consecutive elective percutaneous coronary interventions at a single community center over the 2.5-year period between 1 January 1995 and 30 June 1997.
Results: Abciximab was more common among patients who had recently suffered myocardial infarction, patients with unstable angina, and patients with more complex coronary lesions.
A blinded, randomized trial compared the effects of front-loaded streptokinase with those of the conventional dose of intravenous recombinant tissue-type plasminogen activator (rt-PA) on left ventricular (LV) function after acute myocardial infarction (AMI). Thrombolytic therapy was administered in the emergency departments of 30 community hospitals in central Illinois, and subsequent studies were performed at 1 tertiary referral center. Patients aged < or = 75 years with a first AMI who could be treated within 4 hours of the onset of chest pain were randomly assigned to receive either streptokinase (375,000 IU bolus, followed by 1,125,000 IU over 1 hour) or rt-PA (10 mg bolus, followed by 50 mg in the first hour, and 20 mg/hour for the next 2 hours).
View Article and Find Full Text PDF